Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBITDA (2016 - 2025)

Catalyst Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at $52.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 5.9% year-over-year to $52.7 million; the TTM value through Dec 2025 reached $214.3 million, up 30.7%, while the annual FY2025 figure was $214.3 million, 30.7% up from the prior year.
  • EBITDA reached $52.7 million in Q4 2025 per CPRX's latest filing, roughly flat from $52.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $56.7 million in Q1 2025 to a low of -$30.8 million in Q3 2023.
  • Average EBITDA over 5 years is $28.6 million, with a median of $27.5 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 234.3% in 2023, then soared 242.63% in 2024.
  • A 5-year view of EBITDA shows it stood at $9.2 million in 2021, then soared by 176.05% to $25.5 million in 2022, then surged by 36.84% to $34.8 million in 2023, then surged by 60.72% to $56.0 million in 2024, then decreased by 5.9% to $52.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBITDA are $52.7 million (Q4 2025), $52.8 million (Q3 2025), and $52.2 million (Q2 2025).